Skip to main content

Animations

PD Therapeutics Conference attendees

2024 Parkinson's Disease Therapeutics Conference

Parkinson's Disease Therapeutics Conference

The Parkinson's Disease Therapeutics Conference (PDTC) is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 16th Annual PD Therapeutics Conference is scheduled to be held on October 17, 2024, in New York City.

Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

Thank you for your enthusiasm and interest in this year's conference. Due to overwhelming demand, we have reached full capacity. Registration is now officially closed and unfortunately onsite registration will not be available.  
 

Conference Schedule
7:45 - 8:30
ARRIVALS & BREAKFAST
8:30 - 8:45
WELCOME REMARKS
Sohini Chowdhury | The Michael J. Fox Foundation
Session 1: Progress in the Therapeutics Pipeline
8:45 - 9:00
SESSION INTRODUCTION FROM SESSION CHAIR
Bruce Morimoto, PhD | Alto Neuroscience
9:00 - 9:20
Evaluating the Pre-clinical Efficacy of a mGluR5 Silent Allosteric Modulator, ALX-001 (BMS-984923) in Parkinson's Disease Models and Initiation of a First-in-Patient Phase 1b Study
Timothy R. Siegert, PhD | Allyx Therapeutics
9:20 - 9:40
Discovery of ARV-102 Oral PROTAC® LRRK2 Degrader as a Potential Treatment for Neurodegenerative Disorders
Angela Cacace, PhD | Arvinas, Inc.
9:40 - 10:00
Brain-Penetrant Small Molecule GT-02287 is Well-Tolerated in Healthy Volunteers, Shows GCASE Target Enhancement, and Achieves Therapeutic Exposures Shown to Modulate PD Pathobiology in Pre-Clinical Models
Jonas Hannestad, MD, PhD | Gain Therapeutics, Inc.
10:00 - 10:20
Small Molecule Activation of TRPML1 to Enhance Lysosome Function and Protein Clearance for the Therapeutic Treatment of Parkinson’s Disease
Martin Gill, PhD | Libra Therapeutics
10:20 - 10:30
CLOSING REMARKS BY SESSION CHAIR & AUDIENCE QUESTIONS
Bruce Morimoto, PhD | Alto Neuroscience
10:30 - 11:00
NETWORKING BREAK / POSTER VIEWING
Session 2: Emerging Tools Enabling Clinical Development
11:00 - 11:10
SESSION INTRODUCTION BY SESSION CHAIR
Mark Frasier, PhD | The Michael J. Fox Foundation
11:10 - 11:30
Substantia Nigra Neuromelanin-sensitive MRI and Iron-sensitive MRI Measures: Progress Toward Monitoring and Enrichment Applications in Parkinson's Disease Trials
Daniel Huddleston, MD | Emory School of Medicine
11:30 - 11:50
Investigation of Pathological a-Synuclein in the Skin as Biomarker for Parkinson's Disease
Roland Heym, PhD | AbbVie, Inc.
11:50 - 12:05
Challenges and Opportunities in Clinical Trial Endpoints
Peter Chin, MD, MSHS | Denali Therapeutics
12:05 - 12:35
PANEL | Progress on Clinical Trial Endpoints
Moderator: Catherine Kopil, PhD | The Michael J. Fox Foundation
Peter Chin, MD, MSHS | Denali Therapeutics; Johan Hellsten, PhD | Lundbeck; Tiago Mestre, PhD | University of Ottawa; Thomas Morel, PhD | UCB
12:35 - 1:40
LUNCH / NETWORKING BREAK / POSTER VIEWING
1:45 - 2:15
PANEL | Returning Personal Research Information: A Right and a Need
Moderator: Maggie Kuhl | The Michael J. Fox Foundation
Angela Bradbury, MD | University of Pennsylvania; David Leventhal, MBA | Pfizer; Kevin Kwok, PharmD | MJFF Patient Advocate; Thomas Tropea, DO | University of Pennsylvania
2:15 - 2:25
CLOSING REMARKS BY SESSION CHAIR & AUDIENCE QUESTIONS
Mark Frasier, PhD | The Michael J. Fox Foundation
2:25 - 2:45
NETWORKING BREAK / POSTER VIEWING
Session 3: A New Framework for Conceptualizing Neurodegenerative Disease
2:50 - 3:10
SESSION INTRODUCTION BY SESSION CHAIR
Tanya Simuni, MD | Northwestern Fienberg School of Medicine
3:10 - 3:30
CSF αSyn-SAA and Alzheimer’s Disease Profiles in Presentation and Cognitive Progression in Dementia with Lewy Bodies
David Coughlin, MD, MTR | University of California San Diego
3:30 - 3:50
Clinical and Biological Characteristics of Negative CSF a-Syn SAA PPMI Participants with Diagnosis of Sporadic PD at Baseline
Kathleen Poston, PhD | Stanford University
3:50 - 4:10
a-Synuclein in the Context of Co-pathology and Dementia
Duygu Tosun-Turgut, PhD | University of California San Francisco
4:10 - 4:40
PANEL | How NSD-ISS, ATN and Biomarker Tools will Transform Therapeutic Development for Neurodegenerative Diseases
Moderator: Diane Stephenson
Bruce Morimoto, PhD | Alto Neuroscience; Mark Frasier, PhD | The Michael J. Fox Foundation; Tanya Simuni, MD | Northwestern Feinberg School of Medicine; Billy Dunn, MD | Senior Advisor to MJFF
4:40 - 4:45
CLOSING REMARKS
Sohini Chowdhury | The Michael J. Fox Foundation
4:45
NETWORKING BREAK / POSTER VIEWING / COCKTAIL HOUR
Meet the Session Chairs
  • Bruce Headshot

    Bruce Morimoto, PhD

    Vice President, Drug Development | Alto Neuroscience

    Bruce Morimoto, PhD, has spent his career leading project teams in developing innovative medicines for neurodegenerative diseases like PD, AD, ALS and FTD. His responsibilities have encompassed a broad range of drug development activities including manufacturing, nonclinical safety testing, regulatory affairs and translational clinical research. Morimoto held leadership roles at Allon Therapeutics, Celerion, Alkahest, and Cerecin. He is on the advisor boards of several biotech companies helping to develop and deploy scientific, regulatory and medical strategy. Morimoto started his career on the faculty in the Chemistry Department at Purdue University. He earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA) under the mentorship of Daniel E. Atkinson, and completed post doctorate training at University of California, Berkeley with Daniel Koshland Jr. 

  • Mark Headshot

    Mark Frasier, PhD

    Chief Scientist | The Michael J. Fox Foundation for Parkinson's Research

    Mark Frasier, PhD, joined The Michael J. Fox Foundation (MJFF) in 2006. As Chief Scientist, Frasier regularly meets with academic and industry researchers around the world to identify promising proposals to support, providing troubleshooting and ongoing management of projects as they go forward. He also supports the Foundation's priority interest in developing biomarkers for Parkinson's disease that will accelerate clinical trials of new drugs. Frasier earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug-discovery research in Parkinson's and Alzheimer's disease. In addition to his work as a Foundation scientist, Frasier is a Team Fox member, running the New York ING Marathon and playing golf to raise critical funds for research. 

  • Tanya Simuni Headshot

    Tanya Simuni, MD

    Professor of Neurology, Director, Parkinson's Disease and Movement Disorders Center| Northwestern University Feinberg School of Medicine 

    Tanya Simuni, MD, joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region. She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees for PSG and the PF. She is the Site PI and Steering Committee member for the largest PD biomarker initiative (PPMI study) and site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT). Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the Parkinson’s Study Group.

Posters
  • Poster Presentations

    Understanding Diversity in a Global Parkinson's Disease Cohort

    Maggie Kuhl | The Michael J. Fox Foundation

     

    The Aligning Science Across Parkinson’s Initiative: Changing the Way Science is Done to Accelerate Discoveries in Parkinson’s Disease Research

    Ekemini Riley, PhD | Aligning Science Across Parkinson's

    Sonya Dumanis, PhD | Aligning Science Across Parkinson's

     

    Neuron-derived Extracellular Vesicles from Human Blood for Alpha-synuclein Assessment in Diverse Synucleinopathies

    Erez Eitan, PhD | Neurodex 

     

    Optimization of MDS-UPDRS for Use in Early-stage Parkinson’s Disease Clinical Trials

    Diane Stephenson, PhD | Critical Path Institute

    Thomas Morel, PhD | UCB 

     

    Integrated, Collaborative, Multimodal Data Approach in Parkinson’s Disease

    John Seaman, PhD | Novartis

     

    Targets to Therapies: A New Target De-Risking Initiative at MJFF

    Darryle Schoepp, PhD | Independent Consultant

    Steven Braithwaite, PhD | Bayshore Global Management

    Virginie Buggia-Prevot, PhD | Valo Health

     

    Advanced Quantification and Standardization of Dopaminergic Imaging Markers with the Centamine Scale

    Roger Gunn, PhD | XingImaging

Conference Sponsors

The 16th annual Parkinson's Disease Therapeutics Conference is made possible by the generous support of our sponsors. 

Gold Sponsors: 

Mitsubishi Tanabe Pharma America | NeuroDerm

UCB Pharmaceuticals | Novartis

sponsor logo block

 

 

Interested in Sponsorship Opportunities?

View our sponsorship opportunities menu to support this year's conference.

Interested in learning more? Get in touch: researchpartnerships@michaeljfox.org

About the Venue

Address

Quorum by Convene 
1221 Avenue of Americas
New York, NY 10020

Convene - MJFF PDTC
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.